Daclatasvir
Back to searchMolecule Structure
Scientific Name
Daclatasvir
Description of the Drug
Daclatasvir is a direct-acting antiviral agent used to treat specific hepatitis C virus (HCV) infections in combination with other antiviral agents.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09102
http://www.drugbank.ca/drugs/DB09102
Brand Name(s)
Daklinza
Company Owner(s)
Bristol-Myers Squibb Co
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Nonstructural protein 5A | SINGLE PROTEIN | INHIBITOR | CHEMBL3307224 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL2756027 | SCHEMBL17897804 | |
| PharmGKB | PA166128167 | ||
| DrugBank | DB09102 | ||
| PubChem: Thomson Pharma | 57269885 | ||
| PubChem | 25154714 | ||
| Nikkaji | J2.827.385A | ||
| BindingDB | 50387084 | ||
| DrugCentral | 4875 | ||
| ChemicalBook | CB52515028 | ||
| Guide to Pharmacology | 11266 | ||
| rxnorm | DACLATASVIR | DAKLINZA | DACLATASVIR DIHYDROCHLORIDE |
| ChEBI | 82977 | ||
| ZINC | ZINC000068204830 |
